MEIS2

Across TCGA pan-cancer cohorts, MEIS2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MEIS2 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MEIS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MEIS2 expression acts as an unfavorable survival marker.

CCRCC and GBM are the cancer types where MEIS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.401	0.982	.001	32	view →
GBM	DFS	Quartile	All	0.325	0.795	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MEIS2–CCRCC (OS)

Open the CCRCC breakdown →